However, only poor data are known about safety and efficacy of diltiazem in this setting. The aim of our study was to evaluate the safety and efficacy of different vasodilators in the prevention of RAS during transradial PCI. Methods: 332 patients were consecutively randomized to blindly receive diltiazem 5 mg (n ϭ117), verapamil 2.5 mg (nϭ109), or isosorbide dinitrate 1 mg (n ϭ106) in three centers (Paris, France). All study drugs were administrated through the arterial sheath. The primary end point was the occurrence of a severe RAS defined by the operator as severe limitation of the catheter movement, with or without angiographic confirmation. Secondary endpoints included minor RAS, safety events (need for vasopressor, fluids, atropine support) and pain assessment scale. Results: Main characteristics including age, sex, weight, height, diabetes, arterial sheath diameters, and number of coronary catheters used were identical across the three groups. The rate of severe RAS was lowest in patients receiving isosorbide dinitrate (nϭ4, 3.8%), and verapamil (nϭ6, 5.5%), compared to diltiazem (nϭ12, 10.3%) but the difference was not statistically significant (pϭ0.128). The same results were found for minor RAS, respectively 17.4%, 16.0% and 25.6% (pϭ0.147). There was also no significant difference in term of safety events and pain sensation between the different groups. PCI was successful for all patients and no switch to transfemoral was reported in the entire population. Conclusions: Frequency of severe RAS tended to be higher in patients receiving diltiazem compared to verapamil and isosorbide dinitrate during transradial procedures.
Background: Percutaneous approach techniques with closure device after transcutaneous aortic valve implantation (TAVI), have diminished vascular complications, which nevertheless still occur. In this retrospective study we will report incidence and angiographic factors predisposing to major vascular complications, in patients undergoing TAVI using Prostar® XL closure device as a default strategy. Methods: Consecutive patients, who underwent TAVI transfemorally using Prostar® XL, were evaluated. The incidence of vc was evaluated according to VARC criteria. Using arterial angiography, the femoral-iliac arterial tortuosity was adjusted for large arterial diameters, and expressed as the ratio Total Tortuosity/Arterial Diameter (TT/AD). Arterial calcification, the combination of angulation and atheromatosis at the puncture site, and ideal puncture, were evaluated too. In all patients, 30 days follow-up was available. Results: Out of 112 patients treated with TAVI, in 84 patients (42 males (48.8%), 80.2Ϯ5.86 years, AVA: 0.65Ϯ0.14 cm 2 ) the procedure was performed transfemorally. In patients with major vascular complications (17/84 (20.23%)) comparing to those without, arterial calcification (11 pts (64.7%) vs. 8 pts (11.9%), pϽ0.01) and the TT/AD (30.2 Ϯ 11.25 vs. 22.06 Ϯ 8.64, pϽ0.01) were independent predictors. A correlation of the angiographic TT with the one calculated with computed tomography in 10 selected patients was verified (rϭ0.66, pϭ0.013). Additionally, ideal puncture was achieved more frequently among patients without vascular complications comparing to those with major (94.1% vs. 70.6%, p.0.01). Blood transfusions (1.48 Ϯ 0.37 vs. 2.45 Ϯ 0.59, pϭ0.023) and procedural delays (5 Ϯ7.47 minutes vs. 22.71 Ϯ 4.98 minutes, pϽ0.01) were more frequent among patients with major vascular complications (16/17). Finally, mimimum creatinine clearance after TAVI predicted all-cause 30 days mortality (pϭ0.021). Conclusions: Major vascular complications after TAVI with the use of Prostar closure device can be predicted by arterial calcification at the puncture site and TT/AD ratio. Minimum creatinine clearance after TAVI, predicted 30-day mortality. Background: We conducted a meta-analysis to determine whether transradial catheterization is associated with higher patient radiation exposure compared to transfemoral access. Methods: Using various keywords, we conducted search at major electronic databases from 1950 to May 2012.We included original English language articles comparing transradial and transfemoral access and reporting patient radiation dose in dose area product and air kerma. Approximate means and standard deviations were obtained by assuming that data came from a Weibull distribution derived from Monte-Carlo algorithm. Results: A total of 14 studies (3 randomized, 10 prospective, 1 retrospective) were included for analysis. A meta-analysis of all 14 studies revealed no difference in patient radiation dose between transradial and transfemoral access (standard difference in meanϭ0.11, 95% CI Ϫ0.04 to 0.25, pϭ 0.15).Analysis of the randomized studies alone also showed no difference (standard difference in meanϭ 0.079, 95% CI Ϫ0.025 to 0.183, pϭ0.14). Figure-1 shows the forest plot of combined and the randomized studies. . The heterogeneity was high (I squaredϭ 94) with all studies combined, however the heterogeneity decreased after removal of the observational studies (I squaredϭ37). This indicates that most of the heterogeneity came from the observational studies likely a result of biases inherent to non-randomized studies. Begg and Mazumdar's correlation test showed no indication of publication bias (two tailed pϭ 0.36).
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Conclusions:
Transradial catheterization was not associated with higher patient radiation exposure than transfemoral access.
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Did the RIVAL Trial Increase Transradial Coronary Intervention in Patients with Acute Myocardial Infarction? Results from Korea Working Group on Myocardial Infarction Registry
Hye Won Lee 1 , Jinhee Ahn 1 , Kwang Soo Cha 1 , Jeong Cheon Choi 1 , Jong Hyun Choi 1 , Jung Hyun Choi 1 , Taek Jong Hong 1 , Hye Yoon Jang 1 , Jun-Hyok Oh 1 , Eunyoung Yun 1 1 Pusan National University Hospital, Busan, Korea, Republic of Background: The recent RIVAL trial has made substantial contributions to the world of percutaneous coronary intervention (PCI), drawing attention to access site and bleeding complications. However, it is not well known how often the transradial (TR) approach becomes used after the RIVAL trial in real world clinical practice. We aimed to TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM 
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